Media headlines about Recro Pharma (NASDAQ:REPH) have been trending somewhat negative this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Recro Pharma earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 44.2733664304924 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- RSI update: Recro Pharma, Inc. (REPH) Becomes Oversold (nasdaqchronicle.com)
- Recro Pharma ALERT NOTICE: Pawar Announces Important July 30, 2018 Lead Plaintiff Deadline in Class Action … (digitaljournal.com)
- Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive … (globenewswire.com)
- Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal (finance.yahoo.com)
- EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Recro Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 30, 2018 – REPH (finance.yahoo.com)
REPH has been the subject of a number of analyst reports. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a report on Friday, May 25th. Zacks Investment Research lowered shares of Recro Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 15th. Berenberg Bank began coverage on shares of Recro Pharma in a research note on Thursday, April 19th. They issued a “buy” rating on the stock. Janney Montgomery Scott cut their price target on shares of Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a research note on Thursday, May 24th. Finally, ValuEngine raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, April 18th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $12.63.
Recro Pharma opened at $5.02 on Friday, according to MarketBeat. The company has a current ratio of 1.78, a quick ratio of 1.55 and a debt-to-equity ratio of 2.20. Recro Pharma has a 1 year low of $4.78 and a 1 year high of $13.05.
Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%. The firm had revenue of $19.54 million for the quarter, compared to analyst estimates of $17.32 million. equities analysts expect that Recro Pharma will post -3.1 earnings per share for the current fiscal year.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the company’s stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $5.81, for a total value of $1,092,280.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 21.60% of the stock is owned by insiders.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.